Overview

Patient Derived Xenograft Models Market is forecasted to value over USD 240 million by 2027 end and register a CAGR of 15% from the forecast period 2020-2027.

FutureWise Market Research has illustrated a report on the Patient Derived Xenograft Models Market. The report provides an in-depth anatomy of market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.

The Patient Derived Xenograft Models market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Patient Derived Xenograft Models market are:   
• Crown Bioscience Inc. (US)
• WuXi AppTec (China)
• Champions Oncology, Inc. (US)
• The Jackson Laboratory (US)
• ONCODESIGN (France)
• Charles River Laboratories International, Inc. (US)
• EPO Berlin-Buch GmBH (Germany)
• Shanghai LIDE Biotech Co., Ltd (China)
• Xentech (France)
• Horizon Discovery Group PLC (UK)
(Note: The list of the major players will be updated with the latest market scenario and trends)

Patient Derived Xenograft Models Market Segmentation:

By Type           

• Mice Models
• Rat Models

By Tumor Type

• Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)
• Gynecological Tumor Models (breast, ovarian, and cervical tumors)
• Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)
• Urological Tumor Models (renal, prostate, and bladder tumors)
• Hematological Tumor Models (leukemia and lymphoma)
• Other Tumor Models (head & neck cancer, sarcoma, and melanoma)

By Application

• Pre-clinical Drug Development and Basic Cancer Research
• Biomarker Analysis

By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

By Region
• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the market by type, by tumor type, by application, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key countries— China, Japan, Korea, India, Singapore, Indonesia, Australia and rest of Asia
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction

        1.1. Objectives of the Study 

        1.2. Market Definition 

        1.3. Market Scope 

               1.3.1. Years Considered for the Study

               1.3.2. Market Covered

        1.4. Currency 

        1.5. Limitations 

        1.6. Stakeholders 

 2.  Research Methodology 

        2.1. Research Data 
              2.1.1. Secondary Data
                          2.1.1.1. Key Data from Secondary Sources
              2.1.2. Primary Data

        2.1.2.1. Key Data from Primary Sources

        2.2. Market Size Estimation 
        2.3. Market Breakdown and Data Triangulation 

        2.4. Assumptions for the Study  

3. Executive Summary

        3.1. Market Outlook
        3.2. Segment Outlook
        3.3. Competitive Insights

4. Global Patient Derived Xenograft Models Market Variables, Trends & Scope

        4.1. Market Lineage Outlook

        4.2. Penetration and Growth Prospect Mapping

        4.3. Industry Value Chain Analysis

        4.4. Cost Analysis Breakdown

        4.5. Technology Overview

        4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances

5. Global Patient Derived Xenograft Models Market Overview

        5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Patient Derived Xenograft Models Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Patient Derived Xenograft Models Market Analysis Tools
        6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
        6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
        6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
        6.4. Market Entry Strategies
        6.5. Case Studies

7. Global Patient Derived Xenograft Models Market, By Tumor Type Historical Analysis and Forecast 2020-2027 (USD Million)

        7.1 Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)

        7.2 Gynecological Tumor Models (breast, ovarian, and cervical tumors)

        7.3 Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)

        7.4 Urological Tumor Models (renal, prostate, and bladder tumors)

        7.5 Hematological Tumor Models (leukemia and lymphoma)

        7.6 Other Tumor Models (head & neck cancer, sarcoma, and melanoma)
8. Global Patient Derived Xenograft Models Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)

        8.1. Mice Models

        8.2. Rat Models

9. Global Patient Derived Xenograft Models Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)

        9.1. Pre-clinical Drug Development and Basic Cancer Research

        9.2. Biomarker Analysis

10. Global Patient Derived Xenograft Models Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)

        10.1. Pharmaceutical & Biotechnology Companies

        10.2. Contract Research Organizations

        10.3. Academic & Research Institutions

11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        11.1. Introduction

        11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                  11.2.1. U.S.A

                  11.2.2. Canada

                  11.2.3. Mexico

        11.3. Market Size (USD Million) Forecast for North America 2020-2027 

12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        12.1. Introduction

        12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                 12.2.1. Brazil

                 12.2.2. Venezuela

                 12.2.3. Argentina

                 12.2.4. Rest of Latin America

        12.3. Market Size (USD Million) Forecast for Latin America 2020-2027  

13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        13.1. Introduction

        13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                  13.2.1. Germany

                  13.2.2. U.K

                  13.2.3. France

                  13.2.4. Italy

                  13.2.5. Spain

                  13.2.6. Russia

                  13.2.7. Poland

                  13.2.8. Rest of Europe

        13.3. Market Size (USD Million) Forecast for Europe 2020-2027

14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        14.1. Introduction

        14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                  14.2.1. Japan

                  14.2.2. China

                  14.2.3. India

                  14.2.4. Australia and New Zealand

                  14.2.5. ASEAN

                  14.2.6. Rest of Asia Pacific

        14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027

15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)

        15.1. Introduction

        15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                  15.2.1. Saudi Arabia

                  15.2.2. UAE

                  15.2.3. South Africa

                  15.2.4. Egypt

        15.3. Market Size (USD Million) Forecast for MEA 2020-2027           

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)

    16.1 Crown Bioscience Inc. (US)

            16.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.2. Product Portfolio

            16.1.3. SWOT Analysis

            16.1.4. Financial Overview

            16.1.5. Strategic Overview

    16.2 WuXi AppTec (China)

            16.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2. Product Portfolio

            16.2.3. SWOT Analysis

            16.2.4. Financial Overview

            16.2.5. Strategic Overview

    16.3 Champions Oncology, Inc. (US)

            16.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.3.2. Product Portfolio

            16.3.3. SWOT Analysis

            16.3.4. Financial Overview

            16.3.5. Strategic Overview

    16.4 The Jackson Laboratory (US)

            16.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.4.2. Product Portfolio

            16.4.3. SWOT Analysis

            16.4.4. Financial Overview

            16.4.5. Strategic Overview

    16.5 ONCODESIGN (France)

            16.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.5.2. Product Portfolio

            16.5.3. SWOT Analysis

            16.5.4. Financial Overview

            16.5.5. Strategic Overview

    16.6 Charles River Laboratories International, Inc. (US)

            16.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.6.2. Product Portfolio

            16.6.3. SWOT Analysis

            16.6.4. Financial Overview

            16.6.5. Strategic Overview

    16.7 EPO Berlin-Buch GmBH (Germany)

            16.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.7.2. Product Portfolio

            16.7.3. SWOT Analysis

            16.7.4. Financial Overview

            16.7.5. Strategic Overview
    16.8 Shanghai LIDE Biotech Co., Ltd (China)

            16.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.8.2. Product Portfolio

            16.8.3. SWOT Analysis

            16.8.4. Financial Overview

            16.8.5. Strategic Overview

    16.9 Xentech (France)

            16.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.9.2. Product Portfolio

            16.9.3. SWOT Analysis

            16.9.4. Financial Overview

            16.9.5. Strategic Overview

    16.10 Horizon Discovery Group PLC (UK)

            16.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.10.2. Product Portfolio

            16.10.3. SWOT Analysis

            16.10.4. Financial Overview

            16.10.5. Strategic Overview

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures